Denali Therapeutics stock
DNLINASDAQDenali Therapeutics Inc., HealthcareISIN US24823R1059
37Score 37 out of 100, Weak
Price and trend
49 / 100
Price history
+7.8% in one yearThe chart shows daily closes over 9 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 11% below it.
Since October 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is 31% below its 52-week high. Largest decline in 9 years: 88% (December 2020 to April 2025).
Chart figures for advanced users
- SMA 50$19.86
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$21.24
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$16.02
- The lowest closing price of the last twelve months.
- Resistance$27.21
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Denali Therapeutics Inc. belongs to the Biotechnology industry (United States) and, with a market value of $3.56B, is number 91 of 296 companies in its industry on MEQIRI.
- MEQIRI Score 37 out of 100 (Weak): rank 596 of 714 in Healthcare, median 53.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $867.88M, financial debt $36.76M (fiscal 2025).Stability 75
Weaknesses
- DilutionShare count up 61% since 2020.Capital allocation 18
- Loss-makingLoss of $314.42M over the last 12 months.Fundamentals 17
- Turned to a lossEarnings per share from $0.65 in 2020 to −$2.97.Growth 23
Its standout strengths are stability and momentum, while capital allocation and fundamentals hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansValuation
Valuation signal
not measuredClosing price of 11 Nov 2026, used by the daily score.
No fair value can be calculated for this stock, so the signal follows the valuation grade.
Valuation metrics
No fair value can be calculated for this stock from the available figures.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 0%, operating 0%, net 0%. Last 12 months: net −100%.
Debt & balance sheet
Fiscal 2025Debt is low; no interest coverage is reported.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 3 Nov 2026EPS reported $0.37 (expected −$0.27)above expectations
Analyst estimates
Analysts have raised their 2026 earnings estimate by 8.7% since 15 Oct 2026.
- Earnings per share
- −$2.09+8.7%
- Revenue
- $45.63M+17.1%
- Earnings per share
- −$2.32+0.9%
- Revenue
- $146.25M+12.2%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: +1.7%First guidance for the third quarter: net product revenue of $10 million to $12 million, with no earlier comparison; data from one study now come in the first half of 2027.
“Given the pace of adoption, expanding access, and continued strong execution, we expect Q3 net product revenue to be in the range of $10 million to $12 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. 3 insiders sold, $435,303 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Chin Peter ScottSale
4 Sept 2026, Chief Medical Officer
- Shares
- 1,654
- Price
- $22.29
- Value
- $36,868
- Thornberry NancySale
2 Sept 2026, Board
- Shares
- 11,439
- Price
- $22.90
- Value
- $261,929
- Schuth Alexander O.Sale
1 Sept 2026, COFO and Secretary
- Shares
- 2,768
- Price
- $23.44
- Value
- $64,882
Show 1 more
- Schuth Alexander O.Sale
11 Aug 2026, COFO and Secretary
- Shares
- 2,857
- Price
- $25.07
- Value
- $71,625
Partial trades from one filing are shown in one row, with the average price.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Denali Therapeutics
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 37
- Sector median
- 53
Categories against the sector medianMedian of 714 companies
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- AbCellera BiologicsABCL $3.9B38
- Tarsus PharmaceuticalsTARS $3.78B43
- Enliven TherapeuticsELVN $3.77B45
- Iovance BiotherapeuticsIOVA $3.74B43
- Viking TherapeuticsVKTX $3.63B34
- Legend BiotechLEGN $3.61B37
- Arcutis BiotherapeuticsARQT $3.59B62
- Viridian TherapeuticsVRDN $3.55B47
ETFs that hold Denali Therapeutics
Held by 12 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 0.20% | 0.35% | €1.21B |
| Xtrackers Russell 2000 UCITS ETF 1CXRS2 | 0.10% | 0.30% | €2.17B |
| State Street SPDR Russell 2000 U.S. Small Cap UCITS ETF (Acc)ZPRR | 0.10% | 0.30% | €4.22B |
Show 5 more
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.03% | 0.35% | €8.19B |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.02% | 0.43% | €2.48B |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.01% | 0.30% | €944.34M |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.01% | 0.35% | €434.1M |
| UBS MSCI USA Select Factor Mix UCITS ETF USD accUSUE | 0.01% | 0.25% | €175.89M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Jul 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.